Realtime MI with Dr. Rupert
 January 2012

 DECODING CLARA's MOLECULAR SIGNATURE

arrow icon
Audio Version

Greetings!   

 

Clara is a 62 year old patient with a complex past history. 

 

About 20 years ago, she had an early stage cervical cancer removed. Now she presents with masses in her peritoneum/abdomen from the original cervical cancer.

 

Her oncologist had limited experience with the treatment of this type of cancer. He welcomed a second opinion.  

 

The team at Rupert Case Management (RCM) provided two second opinions from world class gynecological oncologists. One of the experts suggested that we consider molecular profiling. 

 

That is when this scientific advance became very important for Clara.

Molecular Profiling

Molecular profiling is a new diagnostic technology. 

 

Each cancer has a unique signature. The signature can be de-coded using biomarker testing. Then the patient's biomarker signature is used to search the world's medical literature for treatment options  based on world wide biomarker research. This search generates an evidence-based treatment protocol . This is revolutionary for cancer patients.

 

Molecular profiling begins with an immuno-histochemistry (IHC) analysis. An IHC test measures the level of important proteins in cancer cells providing clues about which therapies are likely to have clinical benefit and then what additional tests should be run.

 

With a sample of patient tissue, then a gene expression analysis can be done using a microarray. The microarray test looks for genes in the tumor that are associated with specific treatment options.

 

As deemed appropriate, additional tests such as Fluorescent In-Situ Hybridization (FISH) is used to examine gene copy number variation in the tumor. Polymerase Chain Reaction (PCR) or DNA sequencing is used to determine gene mutations in the tumor DNA.

The results from each of these tests are matched with the published findings from thousands of the world's leading cancer researchers. 

 

Based on this analysis, the process identifies potential therapies for patients and their treating physicians to discuss.

 

This is an important starting point for Clara and her team of doctors.

 

Molecular profiling is available for patients requiring chemotherapy. 

 

Molecular profiling makes the process of selecting chemotherapy agents objective and evidence based. This process helps the patient and his/her doctor to make the best decision(s) possible.

To Start the Conversation Call  800-620-7551

The team at RCM will be pleased to assist clients in ordering molecular profiling and co-ordinating all aspects of the process from start to resolution.

 

It all starts with a conversation.

 

So call at any time.

 

800 620 7551

 

We are always pleased to help.

 

 

          Raymond Rupert MD. MBA.
          Founder/Medical Director
          Rupert Case Management Inc.
          1006 Avenue Road
          Toronto, ON M5P 2K8
          direct:     416-488-9412 ext. 103
          24*7:        800-620-7551
          fax:         416-981-8870
          cell:        416-543-6514
          email: [email protected]
          skype: raymondrupert
          www.rupertcasemanagement.com
                            
newHEADER
Join Our Mailing List
 
View our Previous Newsletters